Dr. Andriole discusses targeted therapies in men with prostate cancer who demonstrate BCR

“Men who experience biochemical recurrence after radical prostatectomy or radiation therapy should undergo PET scanning so that they can have specific targeted treatments administered to the site or sites of recurrence rather than [be treated] using the historical type of clinical parameters that we used in the past,” says Gerald L. Andriole, MD.

In this video, Gerald L. Andriole, MD, discusses the takeaways of the study, “Impact of 18F-Fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer; data analysis from two prospective clinical trials,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Andriole is a Robert Killian Royce distinguished professor of urologic surgery at the Washington University School of Medicine in St. Louis, Missouri.